Create issue ticket

20 Possible Causes for propargylamine

  • Antiparkinsonian

    The neuroprotective activity of these drugs has been demonstrated to be associated with the propargylamine moiety, which protects mitochondrial viability and mitochondrial[ncbi.nlm.nih.gov] Google Scholar Chen JJ, Swope DM (2005): Clinical pharmacology of rasagiline: a novel, second-gene- ration propargylamine for the treatment of Parkinson disease.[link.springer.com]

  • Monoamine Oxidase Inhibitor

    The search terms were monoamine oxidase, neuroprotection, Parkinson disease, propargylamine, rasagiline, and selegiline.[ncbi.nlm.nih.gov] The anti-apoptotic-neuroprotective activity was shown to reside in the propargylamine and not the carbamate moiety.[ncbi.nlm.nih.gov] S5795 New Rasagiline Rasagiline is a novel selective and irreversible MAO-B propargylamine inhibitor with in vitro IC50s of 4.43 nM and 412 nM for MAO-B and MAO-A, respectively[selleckchem.com]

  • Neurotoxic Agent

    METHOD FOR THE DETERMINATION OF TETRAHYDROCARBOLINES IN U... 319 CHRONIC TREATMENT WITH 1234TETRAHYDROISO QUINOLINE TIQ AN ENVIRONMENTAL AND ENDOGENOUS SUBSTANCE INDUC... 320 PROPARGYLAMINES[books.google.de]

  • Tacrine

    Abstract A series of tacrine-propargylamine derivatives were synthesised and evaluated as possible anti-Alzheimer's disease (AD) agents.[ncbi.nlm.nih.gov]

  • Oxybutynin

    N-deethylation (Oxy-DE) followed by the oxidation of the secondary amine function to form the hydroxylamine (Oxy-HA), N-oxidation (Oxy-NO) followed by rearrangement of the tertiary propargylamine[ncbi.nlm.nih.gov]

  • Selegiline

    Abstract Selegiline, the R-optical enantiomer of deprenyl (phenyl-isopropyl-methyl-propargylamine), was almost exclusively used MAO-B inhibitor during the past decades to[ncbi.nlm.nih.gov]

  • Pargyline

    .: Propargylamine-induced irreversible inhibition of non-flavin-linked amine oxidases. Biochem. Pharmacol. 23 , 463–466 (1974) Google Scholar Roth, J. A., Gillis, C.[link.springer.com]

  • Drug-induced Hypoglycemia

    Rasagiline mesylate is a novel second-generation propargylamine developed for the management of PD [ 5 ].[jmedicalcasereports.biomedcentral.com] Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol. 2005;45(8):878–94.[jmedicalcasereports.biomedcentral.com]

  • Methylphenyltetrahydropyridine

    This book shows new neuroprotective agents, such as propargylamine derivatives and neurotrophins, and the intracellular mechanism to prevent the activation of apoptotic cascade[books.google.com]

  • Parkinson's Disease

    In the laboratory, the protective effects of propargylamines are characterized by a U-shaped curve; that is, an increase or decrease in the concentration of the propargylamine[doi.org] Neuroprotection in these models appears to be related to a propargyl ring incorporated within the rasagiline molecule rather than to MAO-B inhibition. 20,21 Other MAO-B inhibitors and propargylamines[doi.org]

Further symptoms